The Economist
Tim Rühlig's Commentary, 'The weak point: Why pharmaceutical security belongs at the heart of European defence', was cited by The Economist in an article on Europe's response to the 'China shock'.
The article highlights the stress test conducted by the Commentary's authors on 56 active pharmaceutical ingredients, which found that more than a third are highly dependent on Chinese suppliers and production sites, making them vulnerable to severe supply disruptions.